Apollomics, Inc.
NASDAQ:APLMBiotechnology
+$6.03 today
- Market cap
- $52.00M
- Beta
- 1.45
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$25.98
Volume 0.02M
Average 0.02M
APLM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Apollomics, Inc.NASDAQ: APLM
Research & Development · Q4 FY2025 · quarter ended Dec 2025
Research & development declines year over year
Q4 FY2025 research & development of $911K fell 88.1% year over year. Over 3 fiscal years it compounded at -46.2% a year.
Context
- Research & development amounted to 65.1% of revenue in FY2025, down 12342.0 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.53M USD
- Year-over-year change
- -77.5%
- 4-year CAGR
- -37.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.53M | -77.5% |
| FY2024 | 2024-12-31 | 24.57M | -28.2% |
| FY2023 | 2023-12-31 | 34.19M | -3.6% |
| FY2022 | 2022-12-31 | 35.46M | -0.3% |
| FY2021 | 2021-12-31 | 35.57M | — |
Research & Development vs competitors
How APLM compares with its peers on the latest reported figures
- APLM's FY2025 research & development of $5.53M is the lowest of the 2 companies compared; the peer median is $56.93M.
- Research & development amounts to 65.1% of revenue for APLM, versus a peer median of 877.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2024 | $56.93M | — | -15.5% | 877.1% | |
| FY2025 | $5.53M | -77.5% | -46.2% | 65.1% | |
| Peer median (excluding APLM) | $56.93M | — | -15.5% | 877.1% | |
Competitors are the stored peer set for APLM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2K | 323K | 821K | 198K | 8.5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 255K |
| Gross Profit | 2K | 323K | 821K | 198K | 8.25M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% |
| Research & Development | 35.57M | 35.46M | 34.19M | 24.57M | 5.53M |
| Selling, General & Admin | 15.29M | 9.95M | 20.64M | 17.77M | 12.44M |
| Operating Expenses | 50.86M | 45.4M | 54.83M | 42.33M | 17.72M |
| Depreciation & Amortization | 153K | 182K | 103K | 72K | 255K |
| EBITDA | (50.12M) | (43.88M) | (53.45M) | (41.06M) | (9.22M) |
| EBITDA Margin | -2505850.0% | -13586.1% | -6509.9% | -20734.8% | -108.4% |
| Operating Income | (50.86M) | (45.08M) | (54.01M) | (42.14M) | (9.47M) |
| Operating Margin | -2542850.0% | -13957.0% | -6578.9% | -21280.8% | -111.4% |
| Interest Income | 467K | 431K | 753K | 480K | 152K |
| Interest Expense | 83K | 93K | 150K | 179K | 65K |
| Other Income / Expenses | (43.94M) | (195.73M) | (118.58M) | (11.46M) | (1.46M) |
| Income Before Tax | (94.8M) | (240.81M) | (172.59M) | (53.6M) | (10.94M) |
| Pre-Tax Margin | -4739800.0% | -74554.2% | -21022.0% | -27070.2% | -128.7% |
| Income Tax Expense | 1K | 1K | 10K | 259K | 3K |
| Net Income | (94.8M) | (240.81M) | (172.6M) | (53.86M) | (10.94M) |
| Net Margin | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% |
| EPS (Basic) | (23.45) | (61.60) | (231.99) | (52.80) | (7.57) |
| EPS (Diluted) | (23.45) | (61.60) | (231.99) | (52.80) | (7.57) |
| Weighted Avg Shares | 867.96K | 867.96K | 743.97K | 926.47K | 1.45M |
| Weighted Avg Shares (Diluted) | 867.96K | 867.96K | 743.97K | 926.47K | 1.45M |
Apollomics, Inc.
NASDAQ:APLM
Intrinsic Alpha fair value
Locked
Current Price
$17.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.